Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics and Safety of HSK31858 in Hepatic Impairment
NCT07913009Phase 1Recruiting
- Sponsor
- Haisco Pharmaceutical Group Co., Ltd.
- Start
- Mar 2026
- Primary completion
- Dec 2026
- Countries
- 1
01
Overview
Phase 1, open-label trial of HSK31858 in Non-cystic fibrosis bronchiectasis (NCFB) (4 arms), sponsored by Haisco Pharmaceutical Group Co., Ltd. Primary endpoints: Maximum Plasma Concentration, Area Under the Curve from Time Zero to Last Quantifiable Concentration and 1 more. Started Mar 2026; status: recruiting.
02
Drugs
HSK31858
03
Conditions
Non-cystic fibrosis bronchiectasis (NCFB)
Beyond the preview
Go deeper on NCT07913009.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07913009.